Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Other Non-Current Liabilities (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Other Non-Current Liabilities for 12 consecutive years, with $1.3 million as the latest value for Q1 2026.

  • Quarterly Other Non-Current Liabilities rose 2.58% to $1.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Mar 2026, up 2.58% year-over-year, with the annual reading at $1.6 million for FY2025, 35.51% up from the prior year.
  • Other Non-Current Liabilities for Q1 2026 was $1.3 million at Achieve Life Sciences, down from $1.6 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $16.7 million in Q4 2023, with the low at $580000.0 in Q1 2024.
  • Average Other Non-Current Liabilities over 4 years is $3.0 million, with a median of $1.2 million recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities crashed 93.1% in 2024, then skyrocketed 113.79% in 2025.
  • Achieve Life Sciences' Other Non-Current Liabilities stood at $16.7 million in 2023, then crashed by 93.1% to $1.1 million in 2024, then surged by 35.51% to $1.6 million in 2025, then fell by 18.3% to $1.3 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Other Non-Current Liabilities are $1.3 million (Q1 2026), $1.6 million (Q4 2025), and $1.2 million (Q1 2025).